Abstract
Importance Prostate cancer (PCa) risk is understood to be mostly unmodifiable and inherited, but there is evidence that environmental and behavioral factors may also contribute. A recent study of health professional cohorts suggests a healthy lifestyle can mitigate a high inherited risk of lethal PCa. It is unknown how modifiable factors affect PCa risk in more diverse populations.
Objective To determine the effects of healthy lifestyle on PCa risk when accounting for race/ethnicity, family history, and genetic risk in a diverse population.
Design Retrospective analysis of the Million Veteran Program (MVP), a cohort study conducted 2011-2021.
Setting National, population-based cohort of United States military veterans.
Participants All veterans were eligible to participate. 590,750 male participants were available for this study; 281,923 completed the lifestyle survey.
Exposures Smoking status, exercise (strenuous activity ≥ 2 days per week), family history, race, and ethnicity (all self-reported at enrollment). PSA testing and body mass index (BMI, obtained from clinical records). Genetic risk (assessed via a polygenic hazard score using genotype data).
Main Outcomes Age at diagnosis of PCa, diagnosis of metastatic PCa, and death from PCa were assessed via Cox proportional hazards models.
Results On univariable analysis, exercise and not smoking were associated with reduced prostate cancer risk (PCa incidence, metastasis, and death), while higher BMI was associated only with reduced PCa death. Not smoking was independently associated with reduced metastatic PCa (HR 0.54, 95% CI 0.49–0.59, p<10−16) and fatal PCa (HR 0.35, 95% CI 0.30– 0.41, p<10−16) when accounting for exercise, BMI, family history, genetic risk, and race/ethnicity. Exercise was not independently associated with any PCa endpoints. Higher BMI was independently associated with reduced fatal PCa (HR 0.97 95% CI 0.96–0.99, p<0.01). Lifetime cause-specific mortality at age 85 was lower for non-smokers (vs. smokers) among Non-Hispanic White men (0.7% vs. 1.8%) and among Black men (1.7% vs. 6.1%).
Conclusions Smoking is independently associated with increased risk of metastatic and fatal PCa among men of diverse race and ethnicity. This demonstrates that lifestyle factors can mitigate the risk of PCa death in high-risk men.
Question Is a healthy lifestyle associated with reduced risk of fatal prostate cancer in a diverse population?
Findings In a population-based cohort study of 281,923 US military veterans, non-smokers had a slight reduction in risk of being diagnosed with prostate cancer and 0.35 times risk of dying from it, a significant association. Lifetime cause-specific mortality at age 85 was lower for non-smokers among Non-Hispanic White men (0.7% vs. 1.8%) and among Black men (1.7% vs. 6.1%).
Meaning Men who smoke are more likely to develop fatal prostate cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Veterans Health Administration. Grants from the National Institutes of Health. Grants from the National Institute of Aging. Grants from the National Institute of Biomedical Imaging and Bioengineering. Grants from The Prostate Cancer Foundation. The University of California. The Grillo-Marxuach Family Fellowship, Moores Cancer Center, University of California Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Veterans Affairs Healthcare System gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Removed the Agent Orange analysis for separate publication. Added assessment of number of screening tests.
Data Availability
All data produced in the present study are available upon reasonable request to the authors. Access to the raw data in the Million Veterans Program (MVP) is available upon special request through the US Department of Veteran Affairs.
